Sökning: "Activated partial thromboplastin time"

Visar resultat 1 - 5 av 6 avhandlingar innehållade orden Activated partial thromboplastin time.

1. 1. Direct Thrombin Inhibitors in Treatment and Prevention of Venous Thromboembolism: Dose – Concentration – Response Relationships

   Författare :Marie Cullberg; Mats O. Karlsson; Ulf G. Eriksson; Nick H.G. Holford; Uppsala universitet; []
   Nyckelord :Pharmaceutical biosciences; Ximelagatran; pharmacokinetic; pharmacodynamic; activated partial thromboplastin time; utility function; dosing strategy; venous thromboembolism; NONMEM; Farmaceutisk biovetenskap;

   Sammanfattning : For prevention and treatment of thrombotic diseases with an anticoagulant drug it is important that an adequate dose is given to avoid occurrence or recurrence of thrombosis, without increasing the risk of bleeding and other adverse events to unacceptable levels. The aim of this thesis was to develop mathematical models that describe the dose-concentration (pharmacokinetic) and concentration-response (pharmacodynamic) relationships of direct thrombin inhibitors, in order to estimate optimal dosages for treatment and long-term secondary prevention of venous thromboembolism (VTE). LÄS MER

3. 2. The effect of thrombin inhibitors on coagulation activity and generation of activated protein C

   Författare :Rikard Linder; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :;

   Sammanfattning : The direct thrombin inhibitor inogatran was, in the TRIM trial (n=1209), compared with unfractionated heparin (UFH) concerning the effect on cardiovascular end-points in unstable coronary artery disease. The results in TRIM demonstrated a trend towards a benefit for UFH during the treatment phase, which was reduced after drug withdrawal. LÄS MER

4. 3. Surgical trauma, inflammation and tissue injury

   Författare :Leif Törkvist; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :Activated partial thromboplastin time; blood flow; blood pressure; CD18; calcitonin gene-related peptide; dalteparin; glucocorticoids; heparin; intravital microscopy; leukotrienes; myeloperoxidase; neutrophils; stress; surgical flaps; rat;

   Sammanfattning : Surgical tissue trauma is a strong stimulus for local inflammation, including leukocyte recruitment. While such a response may be of importance for the defense against microorganisms, it is also clear that inflammation may contribute to further tissue injury. LÄS MER

5. 4. Coagulation disturbances in the critically ill patient with special reference to prediction of outcome

   Författare :Gunnar Nilsson; Anestesiologi och intensivvård; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Medicine human and vertebrates ; protein C; mortality; intensive care; health economics; global haemostatic tests; blood coagulation disorders; APC-PCI complex; abdominal aortic aneurysm operation; antithrombin; Medicin människa och djur ;

   Sammanfattning : Critically ill patients in intensive care units (ICU) often have coagulation disturbances. Clinical manifestations such as thromboembolism and/or bleeding may result from activation and consumption of coagulation factors and inhibitors. Disseminated intravascular coagulation (DIC) is a severe condition with an often-poor prognosis. LÄS MER

7. 5. Early assessment of efficacy and safety of novel anticoagulants as exemplified by direct thrombin inhibitors. Non-clinical pharmacodynamic studies in vitro and in vivo

   Författare :Margareta Elg; Göteborgs universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; animals; antidote; bleeding; inhibition constant; inogatran; association rate constant; melagatran; thrombin inhibitor; thrombosis; fibrinolysis;

   Sammanfattning : The drawbacks of today's anticoagulants are parenteral use (heparins), a narrow interval between efficacy and bleeding, and the high variability of effect with a consequent need for frequent monitoring (coumarins). The aim of the current studies was to evaluate properties important for efficacy and safety of novel anticoagulants, as exemplified by direct thrombin inhibitors, with non-clinical methods. LÄS MER